Sugi Predict

Sugi Predict / Compounds / SCHEMBL1382292

SCHEMBL1382292

SCHEMBL1382292

COCC(O)Cn1cc(C(=O)Nc2ccc(S(C)(=O)=O)cc2)c(C)c1-c1ccccc1C(F)(F)F

nearest known ligand 0.72

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 5/20 0.72
▸ PTPRC P08575 1/20 0.38
▸ LMNA P02545 2/20 0.37
▸ MAPT P10636 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ ELANE P08246 4/20 0.36
▸ PDE7A Q13946 1/20 0.36
▸ CDK1 P06493 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ KDR P35968 1/20 0.35
▸ AVPR2 P30518 2/20 0.35
▸ GPR27 Q9NS67 2/20 0.35
▸ PTGES O14684 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384476 0.89 NR3C2 (0.66) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL1380184 0.89 NR3C2 (0.66) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL2441389 0.89 NR3C2 (0.72) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL1381210 0.87 NR3C2 (0.53) NR3C2MAPTPDE7AAVPR2GPR27
SCHEMBL2439752 0.87 NR3C2 (0.66) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL17646149 0.84 NR3C2 (0.81) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL1381714 0.84 NR3C2 (1.00) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL29571805 0.84 NR3C2 (1.00) NR3C2PTPRCLMNAMAPTTDP1
SCHEMBL12328573 0.84 NR3C2 (0.49) NR3C2ELANECDK1CDK2KDR
SCHEMBL12296602 0.83 NR3C2 (0.67) NR3C2PTPRCLMNAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4703649-B2 — — 2011-06-15 — — JP claimed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 — — US disclosed
US-8026237-B2 For modulating activity of one or more steroid nuclear receptors and for treatment, prevention, or amelioration of symptoms of disease or disorder related to the activity of receptors; 5-benzo[b]thiophen-2-yl-1,4-dimethyl-1H-pyrrole-3-carboxylic acid (4-methanesulfonyl-phenyl)-amide EXELIXIS, INC. (US) 2011-09-27 — — US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 — — US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 NR3C2 119/4885PTPRC 452/4885LMNA 4213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.